Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study

Fig. 3

A PFS in patients with EGFR-mutant NSCLC treated with standard dose and reduced dose of 2nd G EGFR-TKIs; B TTF in patients with EGFR-mutant NSCLC treated with standard dose and reduced dose of 2nd G EGFR-TKIs. EGFR, epidermal growth factor receptor; PFS, progression-free survival; TTF, time to treatment failure; TKI, tyrosine kinase inhibitor

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us